Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of angiotensin II and angiotensin II type 1 receptor antagonist on the proliferation, contraction and collagen synthesis in rat hepatic stellate cells.

Chinese medical journal·2008
Same author

[Determination of nicotinamide in formula milk powder using liquid chromatography-isotope dilution mass spectrometry].

Se pu = Chinese journal of chromatography·2008
Same author

In vivo tracking of superparamagnetic iron oxide nanoparticle-labeled mesenchymal stem cell tropism to malignant gliomas using magnetic resonance imaging. Laboratory investigation.

Journal of neurosurgery·2008
Same author

Enhancement and broadening of extreme-ultraviolet supercontinuum in a relative phase controlled two-color laser field.

Optics letters·2008
Same author

Screening and breeding of high taxol producing fungi by genome shuffling.

Science in China. Series C, Life sciences·2008
Same author

Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity.

Journal of pharmaceutical sciences·2008

Related Experiment Video

Updated: May 10, 2026

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

Bone metastasis from breast cancer involves elevated IL-11 expression and the gp130/STAT3 pathway.

Li Ren1, Xia Wang, Zuoliang Dong

  • 1Department of Laboratory, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, People's Republic of China. roland-li@163.com

Medical Oncology (Northwood, London, England)
|July 2, 2013
PubMed
Summary

Interleukin-11 (IL-11) is significantly elevated in breast cancer patients with bone metastasis (MBC-B) compared to those with primary breast cancer (PBC). Higher IL-11 levels correlate with increased bone metastasis, suggesting its potential as a predictive biomarker.

More Related Videos

Models of Bone Metastasis
08:49

Models of Bone Metastasis

Published on: September 4, 2012

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

Related Experiment Videos

Last Updated: May 10, 2026

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells
05:02

Modeling Brain Metastasis Via Tail-Vein Injection of Inflammatory Breast Cancer Cells

Published on: February 4, 2021

Models of Bone Metastasis
08:49

Models of Bone Metastasis

Published on: September 4, 2012

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
07:00

Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis

Published on: September 26, 2016

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Breast cancer is a leading cause of cancer-related mortality worldwide.
  • Bone metastasis is a common and serious complication of breast cancer, significantly impacting patient prognosis and quality of life.
  • The molecular mechanisms underlying breast cancer bone metastasis are not fully understood, necessitating further research into key signaling pathways and biomarkers.

Purpose of the Study:

  • To investigate the association between Interleukin-11 (IL-11) and bone metastasis in breast cancer patients.
  • To explore the potential molecular mechanisms involving IL-11 in the development of breast cancer bone metastasis.
  • To evaluate IL-11 as a potential biomarker for predicting bone metastasis in breast cancer.

Main Methods:

  • Serum samples from 180 breast cancer patients and 20 healthy controls were analyzed for IL-11, CTGF, TGF-β, and Tracp5b levels using ELISA.
  • IL-11 mRNA expression in tumor tissues was assessed by RT-PCR.
  • Immunohistochemistry was used to detect IL-11 and CTGF protein expression.
  • Western blot analysis identified the expression of p-38, p-C-JUN, p-STAT3, and p-gp130.
  • Electrophoretic mobility shift assay (EMSA) determined AP-1 DNA-binding activity.

Main Results:

  • Serum IL-11 levels and mRNA expression were significantly higher in patients with breast cancer metastatic to bone (MBC-B) compared to those with primary breast cancer (PBC).
  • Immunohistochemical analysis revealed a higher percentage of IL-11 positive cells in MBC-B tissues (57.5%) versus PBC tissues (14.29%).
  • Elevated expression of p-38, p-C-JUN, p-STAT3, and p-gp130, along with increased AP-1 DNA-binding activity, was observed in the MBC-B group.

Conclusions:

  • Interleukin-11 (IL-11) is significantly associated with the presence and progression of bone metastasis in breast cancer patients.
  • The findings suggest that IL-11 may play a crucial role in the molecular pathways driving breast cancer bone metastasis.
  • IL-11 demonstrates potential as a valuable biomarker for the early prediction of bone metastasis in breast cancer.